Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Annals of the rheumatic diseases · 2011
   Pooled it
2. Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.Joint Commission journal on quality and patient safety · 2019
   Article
3. Leveraging the electronic health record to improve quality and safety in rheumatology.Rheumatology international · 2017
   Review
4. Hepatitis B Serology in Patients with Rheumatic Diseases.The open rheumatology journal · 2016
   Article
5. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.Modern rheumatology · 2011
   Article

Corrections and comments

• Comment on
  Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as